# US 2025/0082772 A1 · Antibody-drug conjugate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082772 A1
- Document ID: US20250082772A1
- Status: Published application
- Kind: A1
- Application number: 18/637,050
- Filed: 2024-04-16
- Published: 2025-03-13
- Earliest claimed: 2016-06-20
- Assignees: Genahead Bio, Inc.
- Applicants: Genahead Bio, Inc.
- Inventors: Tsukasa SUGO; Kenichi MIYATA; Tetsuya OHTAKI
- Web page: https://patentgrep.com/patent/US20250082772A1

## CPC

- A61K 47/6807: {the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 48/0091: {Purification or manufacturing processes for gene therapy compositions}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C07K 16/2881: {against CD71}
- A61K 2039/6056: {Antibodies}
- A61K 2039/627: {characterised by the linker}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Problem: The present invention provides an antibody-drug conjugate (ADC). The present invention also provides a conjugate of an anti-CD71 antibody or an antigen-binding fragment thereof with a drug. The present invention further provides a conjugate of Fab′ with a drug. The present invention further provides a composition comprising the conjugate for delivering the drug to a tissue or a cell of muscle or the like. Solution: A conjugate of an anti-CD71 antibody or an antigen-binding fragment thereof with a drug, and a conjugate of Fab′ of an antibody with a drug.

## Claims

### Claim 1

A conjugate of an anti-CD71 antibody or an antigen-binding fragment thereof with a drug.

### Claim 2 (depends on 1)

The conjugate according to claim 1, wherein the antigen-binding fragment is Fab′.

### Claim 3 (depends on 1)

The conjugate according to claim 1, wherein the anti-CD71 antibody or the antigen-binding fragment thereof is Fab′ of the anti-CD71 antibody.

### Claim 4 (depends on 1)

The conjugate according to claim 1, wherein the drug is a nucleic acid.

### Claim 5 (depends on 1)

The conjugate according to claim 1, wherein the drug is RNA.

### Claim 6 (depends on 1)

The conjugate according to claim 1, wherein the drug is mRNA.

### Claim 7 (depends on 1)

The conjugate according to claim 1, wherein the drug is siRNA.

### Claim 8 (depends on 1)

The conjugate according to claim 1, wherein the drug is an antisense oligonucleotide.

### Claim 9 (depends on 1)

The conjugate according to claim 1, wherein the anti-CD71 antibody or the antigen-binding fragment thereof is linked to the drug via a linker.

### Claim 10 (depends on 1)

A composition comprising the conjugate according to claim 1, for use in delivering a drug to at least one selected from cardiac muscle and skeletal muscle.

### Claim 11

Use of an anti-CD71 antibody or an antigen-binding fragment thereof, for delivering a drug to at least one selected from cardiac muscle and skeletal muscle.

### Claim 12

An anti-CD71 antibody or antigen-binding fragment thereof, for use in delivering a drug to at least one selected from cardiac muscle and skeletal muscle.

### Claim 13 (depends on 1)

A medicament comprising the conjugate according to claim 1.

### Claim 14 (depends on 13)

The medicament according to claim 13, wherein the medicament is a preventive and/or therapeutic agent for a disease of muscle.

### Claim 15 (depends on 13)

A method for prevention and/or therapy for a disease of muscle, comprising administering an effective amount of the medicament according to claim 13 to a mammal.

### Claim 16 (depends on 1)

Use of the conjugate according to claim 1 for manufacturing a preventive and/or therapeutic agent for a disease of muscle.

### Claim 17 (depends on 1)

The conjugate according to claim 1 for use in prevention and/or therapy for a disease of muscle.

### Claim 18

A method for producing a conjugate of Fab′ of an anti-CD71 antibody with a drug, comprising
reacting a thiol group of the Fab′ with a drug having a functional group reactive with the thiol group, or
reacting a thiol group of the Fab′ with a drug bound to a linker having a functional group reactive with the thiol group.
